Akèy › Twoub Somnolans Eksestif
Etid klinik pou Twoub Somnolans Eksestif ap rekrite nan Etazini
15 etid pou Twoub Somnolans Eksestif ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Atlanta, GA9 etid
- San Antonio, TX9 etid
- Cincinnati, OH9 etid
- Charlotte, NC8 etid
- Miami, FL8 etid
- Orlando, FL7 etid
- Austin, TX7 etid
- Columbia, SC7 etid
- Sugar Land, TX7 etid
- Brandon, FL6 etid
- Los Angeles, CA5 etid
- Reading, PA5 etid
- Macon, GA5 etid
- Lansing, MI5 etid
- Baltimore, MD4 etid
- Philadelphia, PA4 etid
- Houston, TX4 etid
- Farmington Hills, MI4 etid
- Boulder, CO4 etid
- Staten Island, NY4 etid
- Colorado Springs, CO4 etid
- Dallas, TX4 etid
- Brooklyn, NY3 etid
- Chicago, IL3 etid
- Phoenix, AZ3 etid
- Madison, WI3 etid
- St. Louis, MO3 etid
- Kansas City, KS3 etid
- Columbus, OH3 etid
- Sterling Heights, MI3 etid
Pa eta
- Alabama7 etid
- Arizona6 etid
- Colorado7 etid
- Florid9 etid
- Georgia10 etid
- Illinois4 etid
- Kalifòni8 etid
- Kansas3 etid
- Maryland4 etid
- Massachusetts4 etid
- Michigan7 etid
- Missouri4 etid
- Nevada3 etid
- New Jersey5 etid
- New York4 etid
- North Carolina9 etid
- Ohio10 etid
- Pennsylvania6 etid
- South Carolina9 etid
- Texas10 etid
- Wisconsin4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
Ap rekriteFaz 2/3
Laj 18 a 70 · Tout sèks · Mizajou Oct 2, 2026 · NCT07598708A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07500090A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 3, 2026 · NCT07455383A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 3, 2026 · NCT07502443A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07540364A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 3, 2026 · NCT07540897A Study of Pitolisant in Patients With Prader-Willi Syndrome
Ap rekriteFaz 3
Laj 6 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06366464A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Ap rekriteFaz 2/3
Laj 18 a 70 · Tout sèks · Mizajou Aug 7, 2026 · NCT06767683Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Jul 24, 2026 · NCT07484217Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Jul 24, 2026 · NCT06568367Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Ap rekriteFaz 2
Laj 18 a 60 · Tout sèks · Mizajou Jun 9, 2026 · NCT06170970Impact of Bright Light Therapy on Prader-Willi Syndrome
Ap rekrite
Laj 6 a 88 · Tout sèks · Mizajou May 15, 2026 · NCT05939453A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Apr 16, 2026 · NCT07096674A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 80 · Tout sèks · Mizajou Dec 24, 2025 · NCT07082829Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 29, 2025 · NCT01793168Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.